Venrock Adviser, LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1615982) · Explore on the interactive board
Venrock Adviser, LLC disclosed 33 US equity positions worth $3.3bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is APGE at 34.2% of the reported book, followed by ORKA, ERAS. The top ten holdings are 80.4% of the book, and the portfolio behaves like about 6 equal-weight positions. Versus the prior filing it opened 4 new positions, added to 5, reduced 5 and exited 4. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Venrock Adviser, LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 4 new, 5 added, 5 reduced, 4 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | APGE APOGEE THERAPEUTICS INC | Healthcare | 34.2% | $1.1bn | 8,493,321 | 0% | held |
| 2 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 12.0% | $394.8m | 4,148,428 | 0% | held |
| 3 | ERAS ERASCA INC | Healthcare | 9.9% | $327.8m | 17,891,812 | 9% | added |
| 4 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 8.0% | $265.0m | 2,985,448 | -19% | reduced |
| 5 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 3.5% | $115.0m | 1,180,000 | 0% | held |
| 6 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 3.1% | $101.6m | 10,346,926 | 0% | held |
| 7 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 2.8% | $93.7m | 3,603,595 | 0% | held |
| 8 | SVRA SAVARA INC | Healthcare | 2.8% | $90.8m | 14,745,943 | 7% | added |
| 9 | JBIO JADE BIOSCIENCES INC | Healthcare | 2.2% | $71.6m | 3,220,364 | 0% | held |
| 10 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.9% | $63.6m | 1,642,166 | -18% | reduced |
| 11 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 1.8% | $59.8m | 3,257,917 | -16% | reduced |
| 12 | VOR VOR BIOPHARMA INC | Healthcare | 1.7% | $56.0m | 3,041,719 | 0% | held |
| 13 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.5% | $48.3m | 2,173,913 | 0% | held |
| 14 | MAZE MAZE THERAPEUTICS INC | Healthcare | 1.4% | $47.8m | 1,602,034 | 0% | held |
| 15 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 1.4% | $47.4m | 6,844,305 | 41% | added |
| 16 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.4% | $46.8m | 4,319,765 | 0% | held |
| 17 | CBIO CRESCENT BIOPHARMA INC. | 1.2% | $38.4m | 2,133,576 | 0% | held | |
| 18 | ZURA ZURA BIO LTD | Healthcare | 1.2% | $38.0m | 6,434,990 | 0% | held |
| 19 | ANL ADLAI NORTYE LTD | 1.1% | $36.9m | 3,212,731 | 0% | held | |
| 20 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.8% | $26.7m | 526,331 | -70% | reduced |
| 21 | HELP CYBIN INC | 0.8% | $25.5m | 3,851,654 | 0% | held | |
| 22 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 0.8% | $25.1m | 1,379,965 | 0% | held |
| 23 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.6% | $21.3m | 8,695,652 | 0% | held |
| 24 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.6% | $19.8m | 2,043,596 | 27% | added | |
| 25 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 0.6% | $18.7m | 4,982,124 | -50% | reduced |
| 26 | ACHV ACHIEVE LIFE SCIENCE INC | 0.5% | $18.0m | 2,751,032 | – | new | |
| 27 | PARABILIS MEDICINES INC | 0.5% | $17.1m | 625,000 | – | new | |
| 28 | SRZN SURROZEN INC | 0.5% | $16.4m | 632,931 | 0% | held | |
| 29 | KRRO KORRO BIO INC | Healthcare | 0.4% | $13.3m | 1,009,500 | 0% | held |
| 30 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 0.4% | $13.2m | 500,000 | 0% | held |
| 31 | XFOR X4 PHARMACEUTICALS INC | 0.3% | $9.0m | 1,934,253 | 485% | added | |
| 32 | RESEARCH ALLIANCE CORP III | 0.1% | $3.2m | 300,000 | – | new | |
| 33 | INM INMED PHARMACEUTICALS INC | 0.0% | $50.7k | 32,685 | – | new |
What did Venrock Adviser, LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| 4XC1 KALVISTA PHARMACEUTICALS INC | 64.6% | $130.3m |
| ENGENE HOLDINGS INC | 16.1% | $32.5m |
| TENX TENAX THERAPEUTICS INC | 13.3% | $26.8m |
| SEPN SEPTERNA INC | 6.0% | $12.2m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 94.4% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Venrock Adviser, LLC's portfolio?
Across every quarter Venrock Adviser, LLC has filed, its median largest position is 30.4% of the book and its median top-ten weight is 76.3%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 4.0 completed holding spells, the median lasted 1.0 quarters; 33.0 positions are still open and their final length is unknown.